Related Experiment Video
Updated: Jul 17, 2026
07:44
Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
Oral Spermidine Supplementation Preserves Submandibular Gland Function After Radiotherapy: Mechanistic Insights and
Yu Min1,2, Kun Gao3, Yingtong Liu4
1Department of Biotherapy Cancer Center West China Hospital Sichuan University Chengdu China.
Medcomm
|July 16, 2026
Summary
Oral spermidine supplementation can protect salivary glands from radiation damage, reducing dry mouth (xerostomia) and improving quality of life for head and neck cancer patients. This metabolite-based strategy shows promising results in clinical trials.
Area of Science:
- Oncology
- Metabolomics
- Proteomics
- Molecular Biology
Background:
- Radiotherapy for head and neck cancer frequently causes salivary gland dysfunction, leading to xerostomia and reduced quality of life.
- Current strategies to mitigate radiation-induced xerostomia are limited.
Purpose of the Study:
- To investigate the potential of spermidine as a protective agent against radiation-induced salivary gland damage.
- To evaluate the efficacy of oral spermidine supplementation in preserving salivary gland function in preclinical models and a clinical trial.
Main Methods:
- Established an irradiation-induced submandibular gland (SMG) injury mouse model.
- Performed integrated proteomic and metabolomic profiling, single-cell RNA transcriptomic analysis, and in vivo/in vitro functional assays.
- Conducted a randomized, double-blind, placebo-controlled clinical trial (NCT07035626) to assess spermidine's effect on xerostomia.
Main Results:
- Spermidine levels were altered in irradiated SMG during recovery.
- Oral spermidine restored salivary flow, preserved aquaporin-5 expression, and reduced tissue damage (vacuolization, apoptosis, fibrosis) in mice and organoids.
- Spermidine increased acinar cell proportion, enhanced secretory gene expression, and suppressed inflammation.
- In the clinical trial, spermidine significantly reduced xerostomia incidence (48.28% vs. 79.31%) and improved salivary output and quality of life.
Conclusions:
- Spermidine supplementation is a safe and effective strategy for preserving salivary gland function post-radiotherapy.
- Spermidine alleviates radiation-induced xerostomia and improves patient quality of life.
- Metabolite-based interventions offer a promising therapeutic avenue for managing side effects of cancer treatment.
